MNPR

Over the past six months, Monopar Therapeutics (MNPR) stock increased by 52.72% to $101.77 as of September 16, 2026, from $66.64 on September 17, 2025, with a 52-week range of $50.07 to $124.82. Recent events include Barclays maintaining a 'Buy' rating and raising its target price to $145 on September 11, 2026, with analysts' consensus indicating an 88.9% upside. The FDA authorized a rolling New Drug Application (NDA) submission for ALXN1840, initiated on July 22, 2026, and ALXN1840 received Rare Pediatric Disease designation on June 30, 2026. Monopar presented positive Phase 3 FoCus trial data for ALXN1840 at AAN 2026 and Phase 2 data at EASL 2026, with two more ALXN1840 presentations scheduled for AASLD – The Liver Meeting® 2026. Q2 2026 financial results reported a net loss of $5.3 million ($0.62 per share) and $134.3 million in cash, expected to fund operations through at least December 31, 2027. Insider transactions showed a 37% reduction in holding by an insider over the last year, a director selling approximately $365k worth of stock on August 26, and collective insider sales exceeding purchases by $2.4 million in the last 12 months. Additionally, Jeffrey D. Kent, M.D., was appointed Executive Vice President, Head of Medical Affairs, effective September 1, 2026, to prepare for potential ALXN1840 FDA approval.